Curis, Inc.

Informe Stock NasdaqCM:CRIS

Capitalización de mercado: US$90.1m

Salud financiera de hoja de balance de Curis

Salud financiera controles de criterios 6/6

Curis tiene unos fondos propios totales de $29.6M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $90.0M y $60.4M respectivamente.

Información clave

216.6%

Ratio deuda-patrimonio

US$42.61m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$56.33m
PatrimonioUS$19.67m
Total pasivoUS$57.61m
Activos totalesUS$77.28m

Actualizaciones recientes sobre salud financiera

Recent updates

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26
Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Nov 03
We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Apr 19
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28
Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04
Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29
We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19
Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17
Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03
What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Análisis de la situación financiera

Pasivos a corto plazo: CRISLos activos a corto plazo ($73.4M) de la empresa superan a sus pasivos a corto plazo ($13.7M).

Pasivo a largo plazo: CRISLos activos a corto plazo ($73.4M) superan a sus pasivos a largo plazo ($46.7M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CRIS tiene más efectivo que su deuda total.

Reducción de la deuda: CRIS tenía fondos propios negativos hace 5 años, pero ahora son positivos y, por tanto, han mejorado.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CRIS tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: CRIS dispone de suficiente liquidez para 1.3 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 4.1% cada año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target